DK3762385T3 - Substituerede 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-oner - Google Patents

Substituerede 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-oner Download PDF

Info

Publication number
DK3762385T3
DK3762385T3 DK19764330.7T DK19764330T DK3762385T3 DK 3762385 T3 DK3762385 T3 DK 3762385T3 DK 19764330 T DK19764330 T DK 19764330T DK 3762385 T3 DK3762385 T3 DK 3762385T3
Authority
DK
Denmark
Prior art keywords
pyrazolo
pyrimidin
dihydro
ones
substituted
Prior art date
Application number
DK19764330.7T
Other languages
English (en)
Inventor
Peter Qinhua Huang
Kevin Duane Bunker
Brant Clayton Boren
Sayee Gajanan Hegde
Hui Liu
Aditya Krishnan Unni
Sunny Abraham
Chad Daniel Hopkins
Sunil Paliwal
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Application granted granted Critical
Publication of DK3762385T3 publication Critical patent/DK3762385T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK19764330.7T 2018-03-09 2019-02-26 Substituerede 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-oner DK3762385T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641149P 2018-03-09 2018-03-09
US201862755163P 2018-11-02 2018-11-02
PCT/US2019/019557 WO2019173082A1 (en) 2018-03-09 2019-02-26 Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Publications (1)

Publication Number Publication Date
DK3762385T3 true DK3762385T3 (da) 2025-05-05

Family

ID=67845731

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19764330.7T DK3762385T3 (da) 2018-03-09 2019-02-26 Substituerede 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-oner

Country Status (23)

Country Link
US (3) US11261192B2 (da)
EP (2) EP3762385B1 (da)
JP (4) JP7300460B2 (da)
KR (2) KR102810102B1 (da)
CN (3) CN111902413B (da)
AU (2) AU2019231551B2 (da)
BR (1) BR112020018286A2 (da)
CA (1) CA3089746A1 (da)
DK (1) DK3762385T3 (da)
ES (1) ES3024692T3 (da)
FI (1) FI3762385T3 (da)
HR (1) HRP20250517T1 (da)
HU (1) HUE071131T2 (da)
IL (2) IL276802B2 (da)
LT (1) LT3762385T (da)
MX (2) MX2020009372A (da)
PL (1) PL3762385T3 (da)
PT (1) PT3762385T (da)
RS (1) RS66798B1 (da)
SG (1) SG11202006906XA (da)
SI (1) SI3762385T1 (da)
TW (2) TWI851451B (da)
WO (1) WO2019173082A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070273A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
KR20200040764A (ko) 2017-07-18 2020-04-20 누베이션 바이오 인크. 1,8-나프티리디논 화합물 및 그의 용도
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CA3126702A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
CA3126931A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
WO2020210380A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
SG11202110615TA (en) * 2019-04-09 2021-10-28 Nuvation Bio Inc Heterocyclic compounds and uses thereof
US20220169646A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
JP7685994B2 (ja) * 2019-11-15 2025-05-30 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 三級アルコールのキラル合成
WO2021127044A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
CA3165474A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
KR20220119419A (ko) * 2019-12-20 2022-08-29 리커리엄 아이피 홀딩스, 엘엘씨 복합제
WO2021127039A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN115867551A (zh) * 2020-05-15 2023-03-28 里科瑞尔姆Ip控股有限责任公司 单一疗法和组合疗法
US20230234956A1 (en) * 2020-06-11 2023-07-27 Recurium Ip Holdings, Llc Methods of making wee1 inhibitor compounds
AU2021290701A1 (en) 2020-06-17 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
CA3188737A1 (en) * 2020-07-09 2022-01-13 Recurium Ip Holdings, Llc Salts and forms of a wee1 inhibitor
WO2022076638A1 (en) * 2020-10-08 2022-04-14 Academia Sinica Catalysts and their uses in one-pot diastereoselective synthesis of remdesivir
CN116848118A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
CN116867787A (zh) * 2021-02-09 2023-10-10 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
EP4322958A4 (en) * 2021-04-12 2025-04-09 Recurium IP Holdings, LLC WEE1 COMPOUND FOR THE TREATMENT OF SEROUS UTERINE CARCINOMA
CN117222648B (zh) 2021-04-30 2026-01-02 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
WO2022251224A1 (en) * 2021-05-28 2022-12-01 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
JP2024526203A (ja) * 2021-06-23 2024-07-17 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｗｅｅ１阻害剤、及びがんを治療するための方法
CN117616029B (zh) * 2021-07-05 2025-09-26 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
WO2023016417A1 (zh) * 2021-08-11 2023-02-16 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
CN117751123A (zh) * 2021-08-31 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的5-氟-7H-吡咯并[2,3-d]嘧啶类化合物
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
WO2023072301A1 (zh) * 2021-11-01 2023-05-04 正大天晴药业集团股份有限公司 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
CN118201930A (zh) * 2021-11-09 2024-06-14 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
KR20240119096A (ko) * 2021-12-15 2024-08-06 리커리엄 아이피 홀딩스, 엘엘씨 암 치료를 위한 병용 요법 사용
CA3235595A1 (en) * 2021-12-15 2023-06-22 Fernando Donate Wee1 inhibitor for cancer
WO2023193789A1 (en) * 2022-04-08 2023-10-12 Beijing Neox Biotech Limited Wee1 degrading compounds
WO2024031048A1 (en) * 2022-08-05 2024-02-08 Recurium Ip Holdings, Llc Wee1 compound for treating uterine serous carcinoma
TW202421151A (zh) * 2022-09-16 2024-06-01 美商瑞卡瑞恩Ｉｐ控股有限責任公司 Ｗｅｅ１抑制劑及用於治療癌症之方法
WO2025076311A1 (en) * 2023-10-06 2025-04-10 Zeno Management, Inc. Solid forms of a wee1 inhibitor
WO2025101691A1 (en) 2023-11-08 2025-05-15 Exelixis, Inc. Methods for treating cancer using compounds that inhibit pkmyt1

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
CA2560691A1 (en) 2004-03-24 2005-10-13 Abbott Laboratories Tricyclic pyrazole kinase inhibitors
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
NZ555474A (en) 2004-12-17 2010-10-29 Astrazeneca Ab 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
WO2007035963A2 (en) 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
MX2009004077A (es) 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
JPWO2008068974A1 (ja) 2006-12-05 2010-03-18 国立大学法人 長崎大学 オーロン誘導体含有診断用組成物
JP5227806B2 (ja) 2006-12-08 2013-07-03 武田薬品工業株式会社 三環性化合物およびその医薬用途
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
US20090156826A1 (en) 2007-12-12 2009-06-18 Wyeth Methods for the preparation of hydroxy-substituted aryl sulfamide compounds
EP2141163A1 (de) 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
JP2012505899A (ja) 2008-10-16 2012-03-08 シェーリング コーポレイション アジン誘導体およびそれの使用方法
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
DE102011108708A1 (de) 2010-09-25 2012-03-29 Merck Patent Gmbh Flüssigkristallanzeigen und flüssigkristalline Medien mit homöotroper Ausrichtung
US8901313B2 (en) 2011-03-16 2014-12-02 Genentech, Inc. 6,5-heterocyclic propargylic alcohol compounds and uses therefor
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
TWI629983B (zh) 2011-10-19 2018-07-21 標誌製藥公司 以ｔｏｒ激酶抑制劑治療癌症
WO2014062454A1 (en) 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CN103864792B (zh) 2012-12-12 2017-01-18 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮并环类化合物
US20160008356A1 (en) 2013-02-28 2016-01-14 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
AU2014223396A1 (en) 2013-03-01 2015-08-27 Amgen Inc. Substituted 7-oxo-pyrido [2, 3-d] pyrimidines and methods of use
JP6702857B2 (ja) 2013-05-14 2020-06-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 液晶媒体および液晶デバイス
CN106458974B (zh) 2014-03-24 2019-07-16 广东众生药业股份有限公司 作为smo抑制剂的喹啉衍生物
WO2016022626A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
KR102388865B1 (ko) 2014-09-05 2022-04-20 메르크 파텐트 게엠베하 제형 및 전자 소자
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
AU2016344040B2 (en) * 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
JP6919977B2 (ja) 2016-03-16 2021-08-18 クラ オンコロジー，インク． メニン−ｍｌｌの置換された阻害剤及びその使用方法
KR20170127101A (ko) 2016-05-10 2017-11-21 삼성디스플레이 주식회사 유기 발광 소자
CN109475567A (zh) 2016-06-09 2019-03-15 布兰克生物股份有限公司 基于硅烷醇的治疗有效载荷
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
KR102673813B1 (ko) 2016-11-04 2024-06-10 삼성전자주식회사 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물
KR102739115B1 (ko) 2016-12-22 2024-12-05 삼성전자주식회사 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물
CN110198943B (zh) 2017-01-23 2021-04-16 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
KR102390377B1 (ko) 2017-03-02 2022-04-25 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
US11248006B2 (en) * 2017-03-23 2022-02-15 Shanghai De Novo Pharmatech Co., Ltd. Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof
KR102496480B1 (ko) 2017-04-25 2023-02-06 삼성전자주식회사 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 조성물
US11101435B2 (en) 2017-05-19 2021-08-24 Arizona Board Of Regents On Behalf Of Arizona State University Tetradentate platinum and palladium complexes based on biscarbazole and analogues
ES2980537T3 (es) * 2017-08-01 2024-10-01 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN109810111B (zh) 2017-11-20 2023-10-27 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111315747B (zh) 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
JP7483620B2 (ja) 2018-02-28 2024-05-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法
WO2019173082A1 (en) 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
KR102637792B1 (ko) 2018-03-22 2024-02-19 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
CN108794493B (zh) 2018-04-28 2020-04-24 北京施安泰医药技术开发有限公司 四氢吡咯并[2,1-h]蝶啶-6(5H)-酮衍生物、其药物组合物、制备方法和应用
CN108794484B (zh) 2018-04-28 2020-04-24 北京施安泰医药技术开发有限公司 [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用
KR102328435B1 (ko) 2018-09-11 2021-11-18 재단법인 대구경북첨단의료산업진흥재단 신규 피리도-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CN109651337A (zh) 2018-12-30 2019-04-19 瑞声科技（南京）有限公司 发光组合物及包含该发光组合物的发光层和电致发光器件
KR102860612B1 (ko) 2019-03-25 2025-09-15 삼성전자주식회사 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물
WO2020210320A1 (en) 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2021127044A1 (en) 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
KR20220119419A (ko) 2019-12-20 2022-08-29 리커리엄 아이피 홀딩스, 엘엘씨 복합제
CA3165474A1 (en) 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations

Also Published As

Publication number Publication date
EP4566612A2 (en) 2025-06-11
WO2019173082A8 (en) 2019-10-17
FI3762385T3 (fi) 2025-03-31
TW202409033A (zh) 2024-03-01
RU2020126590A (ru) 2022-04-11
MX2020009372A (es) 2020-10-14
EP4566612A3 (en) 2025-08-20
AU2023251425A1 (en) 2023-11-09
AU2019231551B2 (en) 2023-08-03
CN117720541A (zh) 2024-03-19
US11261192B2 (en) 2022-03-01
IL302171B1 (en) 2026-01-01
JP2025036624A (ja) 2025-03-14
JP7726563B2 (ja) 2025-08-20
JP2021516242A (ja) 2021-07-01
TWI851451B (zh) 2024-08-01
PL3762385T3 (pl) 2025-06-23
AU2019231551A1 (en) 2020-08-20
IL276802B2 (en) 2023-09-01
NZ766616A (en) 2024-05-31
RS66798B1 (sr) 2025-06-30
EP3762385A4 (en) 2021-11-24
KR20250073542A (ko) 2025-05-27
EP3762385A1 (en) 2021-01-13
ES3024692T3 (en) 2025-06-05
IL276802B1 (en) 2023-05-01
BR112020018286A2 (pt) 2020-12-29
JP7614255B2 (ja) 2025-01-15
KR20200130834A (ko) 2020-11-20
WO2019173082A1 (en) 2019-09-12
CA3089746A1 (en) 2019-09-12
AU2019231551A8 (en) 2020-09-24
CN111902413A (zh) 2020-11-06
US20240391924A1 (en) 2024-11-28
HUE071131T2 (hu) 2025-08-28
MX2023010806A (es) 2023-09-27
TWI822733B (zh) 2023-11-21
JP7300460B2 (ja) 2023-06-29
IL302171A (en) 2023-06-01
IL276802A (en) 2020-10-29
HRP20250517T1 (hr) 2025-06-20
EP3762385B1 (en) 2025-02-12
TW202003512A (zh) 2020-01-16
AU2023251425B2 (en) 2025-11-06
SI3762385T1 (sl) 2025-06-30
SG11202006906XA (en) 2020-09-29
US20210139482A1 (en) 2021-05-13
KR102810102B1 (ko) 2025-05-21
JP2023113969A (ja) 2023-08-16
JP2025160419A (ja) 2025-10-22
CN117285532A (zh) 2023-12-26
US20220024939A1 (en) 2022-01-27
PT3762385T (pt) 2025-05-13
LT3762385T (lt) 2025-05-26
CN111902413B (zh) 2023-10-17

Similar Documents

Publication Publication Date Title
DK3762385T3 (da) Substituerede 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-oner
EP3661918C0 (en) 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS
CL2021001078A1 (es) 2-amino-n-heteroarilo-nicotinamidas como inhibidores de nav1.8.
PT3958977T (pt) Derivados de camptotecina
DK3846904T3 (da) 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
IL290445A (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines
EP3660019C0 (en) 7H-PYRAZOLO[3,4-D]TRIAZINE-2-OXIDES AS EXPLOSIVES
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
DK3768669T3 (da) Piperazinazaspiroderivater
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
LT3402782T (lt) 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
EP3833084A4 (en) CONFIGURATION OF AN OPENFLOW INSTANCE
PT3796975T (pt) Derivados de sulfonilaminobenzamida
PT3419979T (pt) Compostos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
DK3894410T3 (da) Substituerede xanthinderivater
DK3770162T3 (da) Dihydrochromenderivater
EP3757285C0 (en) BRUSHED LEATHERETTE
ITUA20163609A1 (it) "micro-cogeneratore".
EP3740063A4 (en) EPICHLOË-ENDOPHYTE
IL284398B (en) Shuttered switch mirror